The particulars: 10 mg · three weeks · dizziness.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
What is actually going on here, physically?
three weeks at 10 mg is 21 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 10 mg back by 21 days. Whether that reduces dizziness depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 10 mg is 10 mg on day 1 and on day 21. A symptom driven by the rate of change has 21 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot dizziness against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Four half-lives between steps, minimum. Work it out for your agent.
edited 7 Sept 2024 by cake_intact — added the placebo-arm figures
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
It helps to be literal here: liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Slower costs time and nothing else. The ceiling is the same.
edited 7 Sept 2024 by aine_mulcahy — fixed an arithmetic slip in the third paragraph
Put another way, escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
More usefully, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Stepping back is a normal adjustment, not a failure.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Hold rather than escalate while symptoms are active. Always.
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.
The top of the schedule is not the target. The working dose is.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.